Thermo Fisher Scientific Inc. has completed its acquisition of Patheon N.V., a leading contract development and manufacturing organization (CDMO) serving the pharmaceutical and biotechnology sectors, for approximately
USD 7.2 billion.

Patheon generated fiscal 2016 revenue of approximately USD 1.9 billion and will become part of Thermo Fisher's Laboratory Products and Services segment. For the remainder of 2017, the transaction is expected to be approximately USD 0.09 accretive to adjusted earnings per share, which includes
USD 0.02 in the third quarter. Details of the 2017 impact will be provided during Thermo Fisher's third quarter earnings call.

Thermo Fisher continues to expect to realize total synergies of approximately USD 120 million by year three following the close, consisting of approximately
USD 90 million of cost synergies and approximately USD 30 million of adjusted operating income benefit from revenue-related synergies.

Goldman Sachs & Co. acted as financial advisor to Thermo Fisher, and Wachtell, Lipton, Rosen & Katz served as legal counsel. Morgan Stanley & Co. acted as financial advisor to Patheon, and Skadden, Arps, Slate, Meagher & Flom LLP served as legal counsel.

' By adding Patheon's highly complementary CDMO capabilities to our leading clinical trials services and bioproduction technologies, we will be an even stronger partner for our pharmaceutical and biotech customers.'

Marc N. Casper

President and CEO,

Thermo Fisher Scientific


Digital version